Category: Emerging Markets

Postcards from Bangalore 
Posted on Sep 10, 2015

  Last week, we had the good fortune of spending a week in India, along with our colleagues from Ventac Partners. Our trip took us through the cities of Mumbai, Pune, and Bangalore. Our main focus was a visit with a major client, a CDMO with multiple facilities across the country. Here are a few

Made in China: Chidamide 
Posted on Apr 06, 2015

    Today, Derek Lowe points out that Shenzhen Chipscreen received CFDA approval for chid amide (Epidaza), the first drug to be completely discovered, developed and approved exclusively in China. Chidamide is indicated for the treatment of peripheral T-cell lymphoma. The original press release is here, with the company’s product page available here. We’re pleased to

Postcards from Trondheim 
Posted on Mar 23, 2015

  I was privileged to spend 10+ days traveling to Copenhagen (Denmark), Lund (Sweden), and Trondheim (Norway). During my travels, I met with a number of emerging biotech companies, helped teach a class on biotech entrepreneurism, and participated in various internal meetings and discussions with my Ventac Partners colleagues. Sitting in my office in New

The Life Sciences in Wyoming – Part Three of Three 
Posted on Dec 11, 2014

In Part One of his series, Dr. Garrett Lindemann discussed some of the challenges facing Wyoming as it grows its life science industry. In Part Two of this series, Dr. Lindemann highlights some of the life science companies which are already operating in Wyoming. Now, in the third and final installment, Dr. Lindemann summarizes some of the life science companies

BIO Latin America Webinar: Comments and Perspectives 
Posted on Sep 08, 2014

  A few weeks ago, BIO conducted an interesting panel discussion as part of their run up to the BIO Latin America Conference taking place the week in Brazil. The panel included business development professionals from a wide range of companies in Latin America, primarily Brazil. Here are a few comments and issues which stood

Top 10 Drug Products in India 
Posted on Jul 29, 2014

  Do you know which are the top branded drug products in India? We didn’t until we found this handy chart and article.  We took their IMS data a step further by compiling a new table that includes generic names, companies, and sales in US dollars.  A few quick observations: Cough/cold and antibiotics, both short-term

Indian Pharma Industry: Is the sun setting…or rising? 
Posted on Apr 08, 2014

    Much ink has already been spilled discussing the acquisition of Ranbaxy from Daiichi by Sun Pharma in an all stock transaction. A good analysis by a former Ranbaxy executive provides some interesting insights: The valuation of Ranbaxy is attractive at this point in time when USFDA and regulatory issues are at a peak. And

Indian Pharma Market Driven by Exports 
Posted on Jun 20, 2013

    Many people think of the BRIC countries as good domestic opportunities. But as this recent article points out, the Indian export market is growing rapidly.   India’s leading pharmaceutical players will continue to experience revenue growth of over 20% this year, primarily led by exports and especially to the US, says a new report

FDA is right…and wrong 
Posted on Apr 17, 2013

    Today’s issue of FiercePharma covered two interesting FDA decisions (or non- decisions, if you prefer). The first involves the FDA’s decision not to approve generic versions of Purdue’s Oxycontin:   The U.S. Food and Drug Administration today approved updated labeling for Purdue Pharma L.P.’s reformulated OxyContin (oxycodone hydrochloride controlled-release) tablets. The new labeling indicates

No incentive to Indian pharma to innovate 
Posted on Apr 05, 2013

    Very interesting point made by Ranjit Shahani from Novartis India: The immense talents in India’s pharmaceutical companies should be focused on R&D of medicines that will help the people and the economy of India that go far beyond simply copying others’ inventions. Without patents there will be few new medicines and without new medicines

Sandoz closes generic development center in India 
Posted on Dec 05, 2012

Last week, Sandoz announced they are closing a number of generic product development centers around the world, including the Sandoz Development Centre near Mumbai. A few items in this report caught our eye. First, this hat tip to the CRO industry: While a pharma industry expert said the closure of the development centre would mean

Need international out-licensing help? 
Posted on Aug 23, 2012

At Lacerta Bio, we’re in the middle of several international out-licensing projects. This process is enabling us to re-connect with many companies around the world. In addition, we’re making new contacts in other companies, especially in Central/South America, Korea, China, and Japan. The benefits for you are: A current contact list An efficient process A

Pfizer Biocon signals the end for biosimilars? Hardly… 
Posted on Mar 15, 2012

Earlier this week we learned that Pfizer will return to Biocon rights to biosimilar versions of various insulin derivatives: As of March 12, 2012, all rights licensed to Pfizer will revert to Biocon, and all insulin distributed under the brand name UniviaTM and GlarviaTM will be commercially available from Biocon Ltd. only, and will be

KPMG and Future Pharma 
Posted on Oct 21, 2011

Call us late to the party, but in August of this year, KPMG published Future Pharma: Five Strategies to Accelerate the Transformation of Pharmaceutical Industry… The entire report is available here (PDF link) . We won’t rehash the five challenges discussed there (e.g., increased competition, low growth markets, declining R&D productivity, etc.). What we found

Incubating a biotech future for tomorrow 
Posted on Aug 22, 2011

On the one hand, you hate to see talent leaving the US. But, you have to applaud their attitude: “Although we are comfortable in America, we often felt that something was missing,” says YeXin, Duan’s partner in the venture. “The missing piece is a sense of achievement. Though we were well paid at the American

GSK gets it 
Posted on Jul 26, 2011

As FiercePharma correctly points out, GSK’s Q II report reflects the overall industry trends quite accurately: The rest of Glaxo’s report, like the rest of Big Pharma’s Q2 results so far, reflect current industry trends; sales in U.S. and Europe are on the wane, thanks in part to pricing pressures from cash-strapped governments. Cost-cutting helped

The Sandwich Shoppe is Closed 
Posted on Feb 07, 2011

There has been a lot of commentary this week on Pfizer’s announcement that their highly respected research center in Sandwich, UK, will be closed. The original press release suggested that the decision was based on  Pfizer’s decision to exit therapeutic areas such as allergy, respiratory, and urology, which are based in Sandwich. Wall Street analysts loved

Thoughts on JP Morgan Conference 
Posted on Jan 17, 2011

There is a lot of good commentary and analysis of last week’s JP Morgan Healthcare conference, most notably here, here, and here. Here are a few of our thoughts as we look back at the conference: 1. Maybe it’s because it’s the start of a new year, or perhaps it’s that we’ve come out of

More Government Involvement in Pharma Industry 
Posted on Jan 04, 2011

The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil, Russia, and Russia again. Today we learn that the Indian government is reportedly looking to cap foreign direct investment in pharmaceutical (and related) companies to

Brazil’s prescription for pharma: More Government involvement 
Posted on Dec 23, 2010

Earlier this week we wrote about the emerging trend of increasing state government involvement in the pharmaceutical industry. Today we learn about what the government in Brazil is doing. Of interest: The state-led complex’s future evolution poses challenges for Brazil’s health system and domestic producers, as well as for western companies increasingly eager to tap

More on Russia…Is the US Next? 
Posted on Dec 20, 2010

Last week we wrote about the Russian government’s desire to grow their national pharmaceutical infrastructure. Our reading of the situation is that the government will “suggest” that ex-Russia companies who want to do business in the country will be asked to build manufacturing plants, invest in local R&D, etc. Today, Novartis announced a $500 million

Russian government spurs pharma growth 
Posted on Dec 10, 2010

Earlier this week, Prime Minister Putin announced that the Russian government will invest nearly $4 billion to modernize the pharmaceutical industry in Russia. Of note: Putin said he wanted 90 percent of Russia’s vital medicines and 50 percent of its medical equipment to be domestically produced by 2020. Other reports suggest that ~80% of Russia’s

The Indian Connection 
Posted on Nov 22, 2010

The Indian pharmaceutical market is highly fragmented. How can pharma companies make money? PharmaTimes characterizes the market for us in summary form.

Launch evolution across Pharmerging Markets 
Posted on Nov 15, 2010

PharmaPhorum has an excellent analysis on launch evolution across pharmerging markets, such as China, Brazil, Russia, and so forth. A few items of note: 1. The author projects that by 2012, Brazil and China will enter the top 10 largest markets, by sales (with India at #11 and Venezuela at #12). However, they include Germany

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.